Answers are grounded in this paper and cite their sources.
Concurrent inhibition of HDAC and CDK using Roxyl-zhc-84 with additional JAK1 targeting resolved the limited response of traditional HDAC inhibitors in solid tumours via overcoming JAK1-STAT3-BCL2-mediated drug resistance, providing a rational multi-target treatment to sensitize solid tumours to HDACi therapy.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: